ZAP Surgical has secured $36 million in financing led by Catalio Capital Management, following shipment of its 50th ZAP-X system and treatment of nearly 10,000 patients worldwide. The investment will support manufacturing expansion and broader access to self-shielded brain radiosurgery.
RefleXion Medical’s FDA filing for Anchor Point Tracking could extend the reach of SCINTIX autonomous radiotherapy, but clinical evidence and workflow economics remain critical.
GE HealthCare’s MIM Contour ProtégéAI+ 2.0 clearance could speed radiation therapy planning. Find out what changes next.
Proton therapy is precise but hard to scale. Mevion’s Naples win tests whether compact systems can shift access across Southern Europe.
Proton therapy has long had an infrastructure problem. Mevion’s S250-FIT asks whether existing LINAC vaults can change that.
Sensus settled the dispute, but the harder test is SRT adoption. Can reimbursement momentum turn into durable medtech growth?
Preclinical IGRT is powerful but costly. KUBTEC Scientific’s XCELL TomoRad tests whether access, speed, and targeting can finally align.
UNC Health selects Mevion’s compact proton system. Discover what this means for proton therapy economics, workflows, and academic cancer care.
A new phase III clinical trial published in The Lancet has shown that proton therapy significantly improves overall survival and reduces treatment-related toxicities in patients with oropharyngeal cancers compared to traditional photon-based radiation. Conducted across 21 U.S. institutions and led by researchers at the University of Texas MD Anderson Cancer Center, the study is the